

Management of Type 2 Diabetes

- 1. Which of the following is/are true of individuals with type 2 diabetes:**
 - a. Most have a form of insulin resistance
 - b. A state of hyperglycemia occurs because of the inability of cells to accept insulin
 - c. A person without symptoms of type 2 diabetes probably does not have the condition
 - d. All of the above
 - e. a and b only
- 2. What is the glucose level associated with type 2 diabetes diagnosis using the oral glucose tolerance test**
 - a. 100-125 mg/dL
 - b. 140-199 mg/dL
 - c. 200 mg/dL
- 3. What is the current generally accepted level of hemoglobin A1C levels for individuals with type 2 diabetes to achieve?**
 - a. 6% or less
 - b. 7% or less
 - c. 8% or more
- 4. All of the following are associated with the use of metformin therapy except:**
 - a. Reduction in glucose production in the body
 - b. Decrease in hepatic production of glucose
 - c. Hypoglycemia
 - d. Improvement in insulin sensitivity
- 5. Which of the following is/are considered risks when using metformin**
 - a. Lactic acidosis
 - b. Impaired kidney failure or kidney disorders
 - c. Vitamin D deficiency
 - d. All of the above
- 6. Which of the following is not true of incretins**
 - a. Occur naturally in the body in the gastrointestinal tract
 - b. Levels decrease when insulin is introduced in the body
 - c. Have shown a positive effect on beta islet cell preservation
 - d. Endogenous levels of certain incretin peptides are diminished in individuals with type 2 diabetes
- 7. Currently, how many products that impact the incretin system have been approved by the FDA?**
 - a. 1
 - b. 2
 - c. 3
 - d. None
- 8. Which if the following is not true of Januvia?**
 - a. It is an injectable product
 - b. It blocks a receptor site that causes the rapid uptake of incretins after release.
 - c. It has been shown to reduce HA1c levels without weight gain.
 - d. Patients' kidney function should be monitored before or during treatment.
- 9. What are the most serious side effects experienced in the use of Januvia?**
 - a. Gastrointestinal side effects
 - b. Hypoglycemia when used with sulfonylureas
 - c. Cardiovascular problems
 - d. Allergic and hypersensitivity reactions associated with the skin.
- 10. Which of the following properly describes Byetta?**
 - a. It belongs to the class of medications known as TZDs.
 - b. It is an injectable product that acts like insulin.
 - c. It is an incretin mimetic
 - d. It is administered via intramuscular injection
- 11. Which is true of the class of medications known as TZDs?**
 - a. They are available at combination products with other oral hypoglycemic agents.
 - b. They are known as insulin sensitizers.
 - c. They are not known to cause hypoglycemia.
 - d. All of the above
- 12. Which of the following is considered the greatest benefit of the use of TZDs?**
 - a. Favorable cardiovascular side effect profile.
 - b. Preserving beta-cell function over the long term.
 - c. Reduces the number of insulin-sensitive adipocytes
- 13. Which of the following is false regarding the ACCORD study?**
 - a. Patients with type 2 diabetes experienced cardiovascular incidents when HgA1c levels were 6% or less.
 - b. Cardiovascular incidents occurred only when a patient used specific classes of oral hypoglycemic agents
 - c. More aggressive glucose control seemed to correlate with higher rates of cardiovascular events.
 - d. The study could challenge the long-standing notion of the cardiovascular benefits of tight glucose control.
- 14. Pharmacists are prohibited from becoming certified diabetic educators.**
 - a. True
 - b. False
- 15. What should pharmacists do with a patient who might be at risk for experiencing cardiovascular adverse effects when using TZDs?**
 - a. Immediately recommend discontinuation of the product.
 - b. Discuss the potential symptoms associated with cardiovascular disease with the patient and look for existing symptoms.
 - c. Discuss the potential for a gradual change to other products under the supervision of a physician.
 - d. All of the above.
 - e. b and c only.

NOTE: THIS DOCUMENT IS NOT VALID FOR CREDIT. DO NOT MAIL THIS DOCUMENT TO ELF PUBLICATIONS. YOU SHOULD COMPLETE THE EXAM ONLINE.